諾瓦瓦克斯醫藥 NVAX 深 滬
等待開盤 04-01 09:30:00 美东时间
8.14
+0.050
+0.62%
華盛通- 最 高8.39
- 今 開8.27
- 成交量 599.43万股
- 最 低 7.715
- 昨 收 8.09
- 總市值 13.27亿
- 52周最高 11.97
- 市盈率 靜 3.20
- 換手率 3.68%
- 52周最低 5.80
- 委 比 49.97%
- 總股本 1.63亿
- 歷史最高 331.68
- 量 比 1.76
- 振 幅 8.34%
- 歷史最低 3.5324
- 每 手 1
- 風險率 1.21%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BRIEF-Novavax Appoints Dr. Robert Walker As Executive Vice President And Head Of Research & Development
BRIEF-Novavax Appoints Dr. Robert Walker As Executive Vice President And Head Of Research & Development March 30 (Reuters) - Novavax Inc NVAX.O : NOVAVAX APPOINTS DR. ROBERT WALKER AS EXECUTIVE VICE PRESIDENT AND HEAD OF RESEARCH & DEVELOPMENT Source text: ID:nPn5XntfJa Further company coverage: NVA
03-30 22:03
BUZZ-Novavax rises after naming internal medicine specialist as R&D head
BUZZ-Novavax rises after naming internal medicine specialist as R&D head ** Shares of vaccine maker Novavax NVAX.O rise 1.5% to $8.58 premarket ** Co appoints Robert Walker as executive vice president and head of research and development, effective immediately ** Walker, previously the firm's chief
03-30 20:17
新浪财经ESG：诺瓦瓦克斯医药 MSCI（明晟）ESG评级调升至BB
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点击查看【 ESG评级中...
03-24 10:26
Trump administration reportedly shortlisting CDC nominees
Two physicians with somewhat contrasting views on vaccines are among the potential candidates the Trump administration is considering as its pick to lead the U.S. Centers for Disease Control and Preve...
03-22 00:24
Shares of vaccine stocks are trading higher, possibly after a Massachusetts federal judge blocked parts of Robert F. Kennedy Jr.'s vaccine policy changes.
Shares of vaccine stocks are trading higher, possibly after a Massachusetts fed...
03-18 02:38
美股大行评级 | 下调居多！多邻国、Elastic、Flutter、欧特克、Zscaler等遭多家机构下调目标价
今日重点评级关注：巴克莱：维持C4 Therapeutics"超配"评级，目标价从5美元升至7美元；富国银行：维持Agilon Health"超配"评级，目标价从1美元升至1.5美元
03-02 14:08
What's Going On With Novavax Stock On Friday?
Novavax reported a fourth-quarter profit, guides 2026 revenue between $230 million and $270 million.
02-28 03:20
HC Wainwright & Co. Maintains Buy on Novavax, Raises Price Target to $16
HC Wainwright & Co. analyst Sean Lee maintains Novavax (NASDAQ:NVAX) with a Buy and raises the price target from $11 to $16.
02-27 19:40
COVID-19 Vaccine Maker Novavax Swings To Profit As Sales Climb
Novavax shares jump 21% after posting a surprise profit and 67% revenue growth, while outlining lower 2026 revenue guidance.
02-27 03:19
Novavax shares are trading higher. The company reported Q4 financial results.
Novavax shares are trading higher. The company reported Q4 financial results.
02-26 23:11
